Mesenchymoangioblast-derived mesenchymal stem cells therapy(Cynata Therapeutics)

N/A

Report date: 2024/09/19 17:35:14

Base Information

Drug NameMesenchymoangioblast-derived mesenchymal stem cells therapy(Cynata Therapeutics)
Drug Alias NameCYP-001
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Mesenchymoangioblast-derived
Mechanisms of ActionCell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Graft vs Host DiseaseRespiratory Distress Syndrome, Adult
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesItalyAustralia +[7] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesCynata Therapeutics Ltd
China Registration ClassN/A

Develop Information

Active CompaniesFujifilm CorpCynata Therapeutics Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Graft vs Host DiseaseRespiratory Distress Syndrome, Adult
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A